We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.
- Authors
Molife, L R; Fong, P C; Paccagnella, L; Reid, A H M; Shaw, H M; Vidal, L; Arkenau, H-T; Karavasilis, V; Yap, T A; Olmos, D; Spicer, J; Postel-Vinay, S; Yin, D; Lipton, A; Demers, L; Leitzel, K; Gualberto, A; de Bono, J S
- Abstract
This phase Ib trial assessed safety, tolerability, and maximum tolerated dose (MTD) of figitumumab (CP-751,871), a fully human monoclonal antibody targeting the insulin-like growth factor type 1 receptor (IGF-IR), in combination with docetaxel.
- Publication
British journal of cancer, 2010, Vol 103, Issue 3, p332
- ISSN
1532-1827
- Publication type
Journal Article
- DOI
10.1038/sj.bjc.6605767